特発性肺線維症(IPF)治療薬の世界市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Global Idiopathic Pulmonary Fibrosis 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Pathogenesis
• Signs and symptoms
• Diagnosis
• Management
• Epidemiology

PART 06: Pipeline analysis
• Lebrikizumab
• Tipelukast
• Tralokinumab
• FG-3019
• Simtuzumab
• BMS-986020
• AF-219
• SAR156597
• BG00011
• PRM-151
• PBI-4050

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by ROA
• Oral
• Parenteral

PART 09: Market segmentation by drug class
• Systemic corticosteroids
• Immunosuppressants
• Tyrosine kinase inhibitors
• Anti-fibrotic agents

PART 10: Geographical segmentation
• Global idiopathic pulmonary fibrosis market by geographical segmentation 2015-2020
• Idiopathic pulmonary fibrosis market in Americas
• Idiopathic pulmonary fibrosis market in EMEA
• Idiopathic pulmonary fibrosis market in APAC

PART 11: Market drivers
• Special regulatory designations for pipeline candidates
• Growth in patient population
• Unmet medical needs

PART 12: Impact of drivers

PART 13: Market challenges
• Unknown disease etiology
• Lack of proper diagnosis
• Increased use of off-label and alternative therapies

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Patient assistance programs
• Increase in M&A
• Rise in public awareness

PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• Baxter International
• Boehringer Ingelheim
• F Hoffmann-La Roche
• Prometheus Laboratories
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Common symptoms of idiopathic pulmonary fibrosis
Exhibit 03: Other signs and symptoms of idiopathic pulmonary fibrosis
Exhibit 04: Treatment options for idiopathic pulmonary fibrosis
Exhibit 05: Drugs used in the treatment of idiopathic pulmonary fibrosis
Exhibit 06: Global idiopathic pulmonary fibrosis market: Pipeline portfolio
Exhibit 07: Global idiopathic pulmonary fibrosis market 2015-2020 ($ billions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global idiopathic pulmonary fibrosis drugs market by ROA
Exhibit 10: Global idiopathic pulmonary fibrosis drugs market segment by drug class
Exhibit 11: Global idiopathic pulmonary fibrosis market segmentation by geography 2015
Exhibit 12: Idiopathic pulmonary fibrosis market revenue by geography 2015-2020 ($ millions)
Exhibit 13: Idiopathic pulmonary fibrosis market in Americas 2015-2020 ($ millions)
Exhibit 14: Idiopathic pulmonary fibrosis market in EMEA 2015-2020 ($ millions)
Exhibit 15: Idiopathic pulmonary fibrosis market in APAC 2015-2020 ($ millions)
Exhibit 16: Key drivers
Exhibit 17: Impact of drivers
Exhibit 18: Key challenges
Exhibit 19: Impact of drivers and challenges
Exhibit 20: Key trends
Exhibit 21: Baxter International: Business segmentation by revenue 2014
Exhibit 22: Baxter International: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 23: Baxter International: Geographical segmentation by revenue 2014
Exhibit 24: Baxter International: Key takeaways
Exhibit 25: Boehringer Ingelheim: Business segmentation by revenue 2014
Exhibit 26: Boehringer Ingelheim: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 27: Boehringer Ingelheim: Geographical segmentation by revenue 2014
Exhibit 28: Boehringer Ingelheim: Key takeaways
Exhibit 29: F Hoffmann-La Roche: Business segmentation 2014 by revenue
Exhibit 30: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 31: F Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 32: F Hoffmann-La Roche: YoY growth and revenue generated from CellCept 2011-2014 ($ millions)
Exhibit 33: F.Hoffmann-La Roche: Key takeaways
Exhibit 34: Prometheus Laboratories: Product categories
Exhibit 35: Prometheus Laboratories: Key takeaways


【レポート販売概要】

■ タイトル:特発性肺線維症(IPF)治療薬の世界市場2016-2020
■ 英文:Global Idiopathic Pulmonary Fibrosis 2016-2020
■ 発行日:2016年5月5日
■ 調査会社:Technavio
■ 商品コード:IRTNTR8081
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。